论文部分内容阅读
32例初诊T2DM患者口服瑞格列奈(孚来迪)0.5mg,每日3次。按HOMA模型计算胰岛素抵抗指数(HOMA-IR)和胰岛素分泌指数(HOMA-IS)。结果:12周后,FPG、PG1h、HbA1c下降、FINS水平无明显变化,INS1h明显上升(P<0.01),HOMA-IR均明显下降(P<0.05),HOMA-IS明显增加(P<0.01)。多元回归分析显示餐前及餐后血糖值变化与HOMA-IR的变化相关。结论:瑞格列奈治疗初诊的T2DM,可明显改善胰岛素抵抗和β细胞分泌功能,降低血糖。
Thirty-two newly diagnosed T2DM patients were given repaglinide 0.5 mg three times a day. The HOMA-IR and HOMA-IS were calculated according to HOMA model. Results: After 12 weeks, the levels of FPG, PG1h and HbA1c decreased, FINS level did not change significantly, INS1h increased significantly (P <0.01), HOMA-IR decreased significantly (P < . Multivariate regression analysis showed that changes in pre and postprandial blood glucose levels were associated with changes in HOMA-IR. Conclusion: Repaglinide treatment of newly diagnosed T2DM can significantly improve insulin resistance and β-cell secretory function and lower blood glucose.